This clinical trial is focused on studying the effectiveness and safety of a medication called azenosertib, also known by its code name ZN-c3. The study is specifically for patients with a type of cancer known as High-Grade Serous Ovarian Cancer, which can also affect the fallopian tubes or the lining of the abdomen, known as the peritoneum. The purpose of the study is to evaluate how well ZN-c3 works in treating this cancer and to understand any side effects it may cause.

Participants in the study will receive ZN-c3 in the form of film-coated tablets taken orally. The study will be conducted in two parts. In the first part, the focus will be on determining the safety and how well patients can tolerate ZN-c3. The second part will investigate the medication’s ability to reduce or eliminate the cancer. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of ZN-c3.

The study will take place over a period of time, with regular check-ups and assessments to monitor the participants’ health and the cancer’s response to the treatment. The goal is to gather information that could lead to better treatment options for patients with this type of cancer. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.